St. Racheal’s Pharma Launches New Brands of Antibiotics


– Pledges commitment to improving life expectancy of Nigerians

A leading innovative pharmaceutical company, St. Racheal’s Pharma, has launched its own brands of antibiotics: Amoxicillin/Clavulanic acid 625mg, Ampicillin/Cloxacillin 500 mg and Cefuroxime 250mg. The newly introduced antibiotics, the company said are, to help tame infections and improve the life expectancy of Nigerians.

St. Racheal’s Pharma launches new brands of antibiotics
L-R: Pharm. Jimi Agbaje, chairman of the occasion; Mrs Olubamiwo Adeosun; Pharm. Akinjide Adeosun, chairman/CEO, St. Racheal’s Pharma and Mr Paul Polman, CEO, Unilever, during the launch of St. Racheal’s antibiotics in Lagos, recently.

Speaking at the official launch of the products, held recently at Radison Blu Hotel, Ikeja GRA, Lagos, Pharm. Akinjide Adeosun, chairman and chief executive officer of St. Racheal’s Pharma reiterated that the company was committed to improving life expectancy of Nigerians and by extension Africans through the provision of to quality pharmaceuticals, adding that the company was aligning with the United Nations (UN) Sustainable Development Goals (SDGs) 3 – good health and well-being; and 4 – quality education.

In his opening remarks at the colourful ceremony, Pharm. Jimi Agbaje, managing director, Jaykay Pharmaceuticals and Chemical Company Limited, who chaired the occasion, commended Pharm. Adeosun for his boldness in starting the company, noting that St. Racheal’s quality and affordable pharmaceuticals will boost the quest for improved life expectancy in Nigeria and Africa.

Dr John Ahukannah who spoke on the topic, “Life Expectancy in Africa”, at the event, charged governments of African countries to provide quality healthcare policies and sustainable healthcare financing to increase life expectancy rate.

Ahukannah stated further that the state of the economy of most African countries play a huge role in the low life expectancy rate of Africans, adding that many of the countries are unable to build and maintain standard facilities that patients can access.

He lamented that 45 per cent of the African population has no access to clean water which makes it unsurprising that there are several cases of diarrhoea and other water-borne diseases on the continent.

He also bemoaned the prevalence of HIV/AIDs and famine, as well as harmful habits, such as excessive smoking and lack of physical activity, noting that they are factors limiting life expectancy in Africa and urged the government to strengthen the Primary Health Care (PHC) system to serve the population.

While presenting the reports of the pharmacokinetic studies carried out St. Racheal’s antibiotics products, Prof. Cecilia Igwilo, West Africa’s first female professor of pharmacy, said that based on the bioequivalence data of the studies carried out on the products, the NAFDAC approval given to the products is authentic.

The highlight of the occasion was the unveiling of the new products by the top dignitaries at the event led by Pharm. Jimi Agbaje.

Dignitaries at the occasion included: Dr Olayinka Ogunleye, consultant physician, Lagos State University Teaching Hospital (LASUTH), Pharm. Bukky George, CEO, HealthPlus Limited and Mr Paul Polman, CEO, Unilever.